Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
BHP Faces AU$1.3 Billion Wage Adjustment for Queensland...
​Royal Gold to Create Streaming and Royalty Giant...
Chris Berry: The West Must Invest in Refinement...
Torex Gold Moves Beyond Single-Asset Status With Reyna...
Ekin Ober on Why AI Could Be Mining’s...
Maritime Resources: A Low-risk Path to Gold Production...
Stallion Uranium Provides Update on Technology Data Acquisition...
Trump Tariffs to Raise US Medical Device Costs,...
EVs Now Emit 73 percent Less Than Gasoline...
OpenAI to release web browser in challenge to...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

by admin September 23, 2024
September 23, 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved the required response rate to support continued enrolment in the study. Six (6) patients have now recorded confirmed partial responses (PRs) out of 16 assessed at the four-month timepoint, indicating that the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is sufficiently active to support continuation of the trial.

HIGHLIGHTS

Six (6) patients in the Company’s ACCENT trial in pancreatic cancer have now achieved the required reduction in tumour size with no detection of new lesionsThe ACCENT trial can now proceed to recruit the next cohort of 24 patients, giving a total of 50 patients on studyThe ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients

The formal term ‘confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period.

A total of 50 patients are planned for the Phase 2a ACCENT trial. With the six (6) confirmed PRs now obtained, recruitment of the remaining 24 patients in the trial will begin at the existing open trial sites in Australia and South Korea. Recruitment of the second cohort of patients is expected to be completed by end of Q1 2025.

A detailed interim analysis of the Phase 2a trial data obtained to date will be reported in the coming weeks; however, key points are noted below:

Narmafotinib continues to be generally well tolerated by patients with no safety trends identified or dose reductions recorded to dateIn addition to 6 confirmed PRs, there have been 7 patients who have recorded stable disease over 2 or more months, including one patient whose stable disease has improved to achieve a partial response at their 4-month assessment

Amplia CEO and MD Dr Chris Burns commented: “Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial’

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Operations Update
next post
Nordic Nickel Limited (ASX: NNL) – Trading Halt

You may also like

Stock Trend Capital Announces Loan to eGOD Digital...

January 15, 2025

Crypto Market Recap: GameStop Bets on Bitcoin, USDC...

March 27, 2025

Crypto Market Update: Q3 2024 in Review

October 18, 2024

E-Power Resources Inc. Announces Closing of Oversubscribed Hard...

June 21, 2025

AME: Supreme Court of Western Australia approves Scheme

November 29, 2024

10 Largest Producers of Gold by Country

February 13, 2025

2024 Infill Drilling on Satellite Uranium Growth Deposits...

November 20, 2024

Silver Price Surges to US$36, Marking 13 Year...

June 6, 2025

Uranium Stocks: 5 Biggest Companies in 2024

August 10, 2024

CHARBONE Hydrogen and ABB Sign Agreement to Advance...

March 14, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • BHP Faces AU$1.3 Billion Wage Adjustment for Queensland Coal Miners

      July 11, 2025
    • ​Royal Gold to Create Streaming and Royalty Giant in US$3.7 Billion Deal

      July 11, 2025
    • Chris Berry: The West Must Invest in Refinement Now or Fall Further Behind

      July 11, 2025
    • Torex Gold Moves Beyond Single-Asset Status With Reyna Silver Takeover

      July 11, 2025
    • Ekin Ober on Why AI Could Be Mining’s Most Valuable Tool Yet

      July 11, 2025
    Promotion Image

    banner ads

    Categories

    • Business (764)
    • Economy (829)
    • Investing (2,387)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved